Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Dermatology | Family Medicine
Malignant Melanoma Clinical Trials
A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Arizona
Tucson : Call for Information (Investigational Site 0007) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Tucson :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
California
Beverly Hills : Call for Information (Investigational Site 0061) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Encinitas : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
La Jolla : Moores UCSD Cancer Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
La Jolla :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Los Angeles : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
View More »
Los Angeles :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Los Angeles :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Los Angeles : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Los Angeles : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Los Angeles :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Los Angeles :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Los Angeles : Childrens Hospital Of La
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Los Angeles : Call for Information (Investigational Site 0018) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Los Angeles : Call for Information (Investigational Site 0034) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Los Angeles :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Orange : Children'S Hospital Of Orange County
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Orange : Chao Family Comprehensive Cancer Center
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Pleasant Hill : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
San Francisco : St Mary's Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
San Francisco : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Santa Monica : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Santa Monica :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Santa Rosa : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Colorado
Aurora : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Aurora :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Aurora :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Connecticut
New Haven : Yale University School Of Medicine
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Florida
Fort Myers : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Miami Beach : Mount Sinai Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Miami Beach : Call for Information (Investigational Site 0053) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Saint Petersburg : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
St. Petersburgh :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
View More »
Tampa :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tampa :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Illinois
Chicago : Rush University Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Chicago : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Niles : Oncology Specialists, SC
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Park Ridge : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Park Ridge :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Indiana
Goshen : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Indianapolis : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Indianapolis : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Maryland
Bethesda :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Massachusetts
Boston :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Boston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Boston : Dana-Farber Cancer Institute
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Michigan
Detroit : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Detroit :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Minnesota
Rochester :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Missouri
St. Louis :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
St. Louis :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Nevada
Las Vegas :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
New Jersey
Morristown : Atlantic Melanoma Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Randolph : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New York
Bronx : Montefiore Medical Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
New York : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New York : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
New York :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
New York : Memorial Sloan Kettering Cancer Center
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
View More »
New York :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
North Carolina
Charlotte :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Durham : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Durham : Call for Information (Investigational Site 0036) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Winston-salem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Oregon
Portland : Oregon Health and Science University
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pennsylvania
Bethlehem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Bethlehem : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bethlehem : Call for Information (Investigational Site 0001) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Philadelphia : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Pittsburgh : University of Pittsburgh
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
View More »
Pittsburgh :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Tennessee
Memphis :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Memphis : St. Jude Children'S Research Hospital
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Nashville : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Nashville :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Nashville : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
View More »
Nashville : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Nashville : Call for Information (Investigational Site 0033) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Nashville :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Texas
Dallas : Mary Crowley Cancer Research Centers
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Dallas :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Dallas : Mary Crowley Cancer Research Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Dallas :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Dallas : Mary Crowley Cancer Research Center
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
View More »
Houston :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Houston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Houston : University of Texas MD Anderson Cancer Center
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Utah
Salt Lake : Huntsman Cancer Institute
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Salt Lake City : Huntsman Cancer Institute
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Washington
Seattle :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Australia
East Melbourne :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Frankston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Gateshead : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Greenslopes : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Herston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
View More »
Herston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Hobart : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Kurralta Park : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Lismore : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Melbourne : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Melbourne :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
St Leonards : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Tiwi : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Wentworthville :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Westmead :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Austria
Innsbruck : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Wels : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Belgium
Bruxelles : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bruxelles : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Hasselt : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Kortrijk : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Wilrijk : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bosnia and Herzegovina
Banja Luka : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Brazil
Rio de Janeiro : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Sao Paulo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bulgaria
Plovdiv : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Sofia : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Canada
Halifax : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Montreal : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Toronto : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Toronto :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Vancouver : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
View More »
Winnipeg : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Colombia
Medellin : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Croatia
Zagreb : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Czech Republic
Brno : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Hradec Kralove : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Olomouc : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Praha : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Ecuador
Guayaquil : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Portoviejo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Finland
Helsinki : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
France
Bordeaux :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Boulogne Billancourt :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Colmar :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Lille :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Lille :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
View More »
Lyon :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Marseille :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Montpellier :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Nantes :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Nice :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Paris :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Paris :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Pessac :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Rouen :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Vandoeuvre Les Nancy :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Villejuif :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Germany
Essen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Frankfurt :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Freiburg : University Medical Center Freiburg, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Jena : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Kiel :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
View More »
Kiel :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Köln : University Medical Center Collogne, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Mainz :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Mannheim : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Mannheim :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Münster :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tübingen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tuebingen :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Wiesbaden : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Greece
Athens : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Heraklion : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
India
Hyderabad : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Lucknow : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Mumbai : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Nashik : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
New Delhi : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Trivandrum : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Vellore : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Ireland
Cork : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Dublin : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Galway : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Limerick : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Waterford : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Israel
Hod Hasharon : Merck Sharp & Dohme Co. Ltd. Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Jerusalem : Oncology institute, Shaare Zedek Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Oncology Institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel-hashomer :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Italy
Bari : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bergamo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bergamo : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Firenze : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Genova : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Genova :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Meldola : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Milano : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Milano :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Milano :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Napoli : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Napoli : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Napoli : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Padova : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Pisa : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Roma : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Roma :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Siena : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Siena : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Siena :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Udine : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Japan
Tokyo : MSD K.K.
A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)
Korea, Republic of
Seoul : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Lithuania
Klaipeda : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Vilnius : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Macedonia, The Former Yugoslav Republic of
Skopje : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Netherlands
Amsterdam :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Blaricum : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Breda : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Groningen : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Groningen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
View More »
Haarlem : Merck Sharp & Dohme BV Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Maastricht : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Norway
Bergen : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Drammen : MSD (Norge) AS Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Oslo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Peru
Arequipa : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Romania
Timisoara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
South Africa
Bloemfontein : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Cape Town : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Johannesburg : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Pretoria : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Spain
Barcelona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Cordoba : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Granada : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
La Coruna : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
La Laguna (tenerife) : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Leon : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Madrid : Merck Sharp and Dohme de Espana S.A. Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Malaga : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Pamplona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Valencia : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Zaragoza : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Sweden
Jönköping : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Lund : Lunds Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Sollentuna : MSD Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Stockholm : Karolinska Sjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Södersjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
View More »
Umeå : Norrlands Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Switzerland
Glattbrugg : MSD Merck Sharp & Dohme AG Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Turkey
Adana : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Ankara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Antalya : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bornova, Zmr : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Gaziantep : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Istanbul : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Izmir : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Shhiye, Ankara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
United Kingdom
Birmingham : Queen Elizabeth Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Cambridge : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Cambridge : Addenbrooke's Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Edinburgh : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Glasgow : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Glasgow : The Beatson Institute
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Leeds : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Leeds : St James' Institute of Oncology
Study of a DNA Immunotherapy to Treat Melanoma
Leeds : St James Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
London : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Manchester : Christie Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Newcastle Upon Tyne : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Newcastle Upon Tyne :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Northwood : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Northwood :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nottingham : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Nottingham : Department of Clinical Oncology, City Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Oxford : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Oxford : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Oxford : NIHR Biomedical Research Centre
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Southampton : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Southampton : Department of Medical Oncology, Southampton General Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Sutton :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Swansea : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma